Merck to donate 3 million doses of Gardasil to poor countries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

Merck to donate 3 million doses of Gardasil to poor countries

NEW YORK—Merck & Co. has committed to donate at least 3 million doses of it human papillomavirus vaccine Gardasil over the next 5 years for use in demonstration projects in lowest income nations throughout the world. The company made the announcement at the Clinton Global Initiative 2007 meeting. "We are committing to the vaccination of 1 million females against cervical cancer," said Merck's Margaret McGlynn.

Articles in this issue
BRCA1 overexpression is strongly linked to poor outcome in NSCLC patients treated with cisplatin
Bill aims to 'revitalize' FDA by adding powers and databases
New myeloma trial results; two new studies initiated
Neoadjuvant trastuzumab increases pCR rates
Court rejects right of terminally ill to unproven drugs
Sorafenib improves overall survival in Asian HCC pts
Skipping tam doses increases risk of death
The SGR: The madness behind physician payment fee cuts
Dr. Pegram seeks new breast cancer challenges at Miami
SearchMedica.com receives award
FDA adds survival data to Erbitux product labeling
Colon ca chemo: Sequencing or upfront combinations?
FDA oks Campath as first-line Rx of B-CLL
Merck to donate 3 million doses of Gardasil to poor countries
Remembering Hopkins' Martin D. Abeloff, MD, scientist, educator, leader
Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content
Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Ariana Pelosci
February 24th 2025
Article

As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.

Pembrolizumab Plus Chemotherapy Improves OS, PFS in Cervical Cancer

Roman Fabbricatore
December 17th 2024
Article

Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ Years

Julianne Cooley, MS
February 2nd 2023
Podcast

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Cancer Vaccine Combo Does Not Improve PFS in Cervical/Anogenital Tumors

Russ Conroy
October 15th 2024
Article

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Laura Bucher-Bailey, PharmD
September 25th 2024
Article

Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.